Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.
Benevolo G, Drandi D, Villivà N, Castiglione A, Monaco F, Boccomini C, Dessi D, Califano C, Curreli L, Cavallo F, Conconi A, Gaidano G, Rossi FG, Caravita di Toritto T, Ferrante M, Mannina D, Tosi P, Pietrantuono G, Musuraca G, Merli M, Sartori R, Tani M, Freilone R, Varettoni M, Ferrero S.
Benevolo G, et al. Among authors: rossi fg.
Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19920. Online ahead of print.
Br J Haematol. 2024.
PMID: 39604169